Lux Biosciences, Inc. [clinicaltrials_resource:09d741df10f7caf1d2d56aaa61dfad66]
clinicaltrials:NCT00404612clinicaltrials:NCT00404742clinicaltrials:NCT00404885clinicaltrials:NCT00447187Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty [clinicaltrials:NCT00447642]A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) [clinicaltrials:NCT00851734]Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis [clinicaltrials:NCT01243983]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
clinicaltrials:NCT00404612clinicaltrials:NCT00404742clinicaltrials:NCT00404885clinicaltrials:NCT00447187Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty [clinicaltrials:NCT00447642]A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) [clinicaltrials:NCT00851734]Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis [clinicaltrials:NCT01243983]
source [clinicaltrials_vocabulary:source]
Lux Biosciences, Inc. [clinicaltrials_resource:09d741df10f7caf1d2d56aaa61dfad66]
Bio2RDF identifier
09d741df10f7caf1d2d56aaa61dfad66
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:09d741df10f7caf1d2d56aaa61dfad66
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:09d741df10f7caf1d2d56aaa61dfad66
title
Lux Biosciences, Inc.
@en
type
label
Lux Biosciences, Inc. [clinicaltrials_resource:09d741df10f7caf1d2d56aaa61dfad66]
@en